Two‐year follow‐up of transcatheter aortic valve replacement in low‐risk patients with symptomatic...
Background In 2019, the US Food and Drug Administration (FDA) approved transcatheter aortic valve replacement (TAVR) for low-risk patients with symptomatic severe tricuspid aortic stenosis. However...
onlinelibrary.wiley.com